MicroRNA-381 regulates the occurrence and immune responses of coronary atherosclerosis via cyclooxygenase-2

KAIYOU SONG¹, LIANTING LI¹,², GUILING SUN¹ and YANJIN WEI¹

¹Department of Cardiology, Linyi People's Hospital, Linyi, Shandong 276003; ²Department of Internal Medicine, Junan Hospital of Traditional Chinese Medicine, Linyi, Shandong 276600, P.R. China

Received September 28, 2016; Accepted June 5, 2017

DOI: 10.3892/etm.2018.5947

Abstract. The present study aimed to measure the levels of microRNA-381 (miR-381) in the plaque tissues, peripheral blood mononuclear cells (PBMCs) and serum of patients with coronary atherosclerosis. In addition, the regulatory mechanisms of miR-381 and cyclooxygenase (COX)-2 in coronary atherosclerosis were investigated. A total of 36 patients with coronary atherosclerosis who received coronary endarterectomy at Linyi People's Hospital and Junan Hospital of Traditional Chinese Medicine (Linyi, China) between January 2013 and June 2016 were enrolled into the present study, while 39 healthy subjects were included as the control group. Peripheral blood was collected from all patients and healthy subjects. Plaque tissues were resected from patients with coronary atherosclerosis and adjacent artery intimal tissues were resected as the control tissues. Using quantitative polymerase chain reaction, the levels of miR-381 and COX-2 mRNA in the plaque tissues, PBMCs and serum were determined. In addition, COX-2 protein expression in the plaque tissues and PBMCs was measured by western blotting, while enzyme-linked immunosorbent assay was utilized to examine the protein content in the serum. To identify the direct interaction between miR-381 and COX-2 mRNA, dual-luciferase reporter assay was also conducted. The levels of COX-2 mRNA and protein in the plaque tissues, PBMCs and serum of patients with coronary atherosclerosis were significantly elevated compared with those in the corresponding control groups. However, the expression of miR-381 was significantly reduced in the coronary atherosclerosis patients. Dual-luciferase reporter assay revealed that miR-381 was able to directly target the 3’-untranslated region of COX-2 mRNA to regulate the expression of COX-2. Therefore, the present study demonstrated that enhanced levels of COX-2 expression in patients with coronary atherosclerosis are associated with the downregulation of miR-381 expression, while miR-381 may regulate the occurrence and immune responses of coronary atherosclerosis via COX-2.

Introduction

Coronary atherosclerosis is a serious vascular disease, which may lead to coronary artery stenosis that is a common cause of angina and myocardial infarction (1). Long-term myocardial ischemia and hypoxia can result in heart enlargement, decrease of compliance and myocardial contraction dysfunction, leading to chronic heart failure (2). Coronary atherosclerotic plaque, particularly the vulnerable plaque of the coronary artery with a thrombus formation tendency, is one of the most important reasons for coronary artery stenosis (3). Coronary atherosclerosis has a greater impact on the quality of life of patients, due to its long clinical treatment, easy relapse and poor prognosis. Therefore, studies on coronary atherosclerosis at the molecular level are important for the clinical treatment of coronary atherosclerosis.

MicroRNAs (miRNAs or miRs) are a class of non-encoding RNA molecules with 18-22 nucleotides in eukaryotes, which regulate the expression of their target proteins at the mRNA level (4-6). Altered expression of various miRNA molecules and a variety of proteins in coronary atherosclerosis suggests that miRNAs serve important roles in the regulation of proteins that are associated with coronary atherosclerosis (7,8). Studies have demonstrated that atherosclerosis is a type of artery intimal inflammation with a series of basic features of inflammation (9,10). Furthermore, cyclooxygenase (COX)-2 is a key inflammatory factor in the human body. Activation of the COX-2 signaling pathway causes and aggravates the pathogenesis of atherosclerosis (11). Atherosclerosis can be considered chronic inflammation. COX-2 is an important rate-limiting enzyme in the synthesis of prostaglandin and thromboxane from arachidonic acid and is highly expressed at inflammatory sites (12). It has been demonstrated that COX-2 is expressed in atherosclerotic lesions and is regulated by a variety of inflammatory cytokines, including IL-1, IFN-γ and TNF-α (12). The metabolites of COX-2 also promote inflammation, indicating that COX-2 is involved in the pathological process of atherosclerosis occurrence and development (13,14). However, the
mechanism of COX-2 regulation on coronary atherosclerotic plaques remains unclear.

In the present study, the expression levels of COX-2 mRNA and protein in the plaque tissues, peripheral blood mononuclear cells (PBMCs) and serum of coronary atherosclerosis patients were examined. In addition, the association between miR-381 and COX-2 was also investigated.

Materials and methods

Patients. A total of 36 patients with coronary atherosclerosis who received coronary endarterectomy at Linyi People’s Hospital and Junan Hospital of Traditional Chinese Medicine (Linyi, China) between January 2013 and June 2016 were enrolled into the present study, including 19 males and 17 females (age range, 38-72 years; median age, 59 years). In addition, 39 healthy subjects were enrolled into the control group, including 18 males and 21 females (age range, 39-75 years; median age, 61 years). All patients with coronary atherosclerosis were diagnosed by electrocardiography, echocardiography and coronary angiography. None of the patients had any complications or infections in the liver or kidney, or immune-associated diseases. Subjects in the control group did not suffer from coronary atherosclerosis. The age, gender, history of diabetes and history of hypertension of all patients were recorded. Gensini scoring scale (15) was used to evaluate the degree of coronary atherosclerosis. For severity scoring, stenosis with 0-<25, 25-50, 50-75, 75-90 and >90% luminal diameter reduction scored 1, 2, 3, 4 and 5 points, respectively. Segment multiplying factors for the left main trunk, proximal left anterior descending branch, middle left anterior descending branch, D1 diagonal branch, D2 diagonal branches, proximal left circumflex branch, distal left circumflex branch, posterior descending branch, posterior lateral branch and the proximal, middle and distal right coronary artery was 5, 2.5, 1.5, 1, 0.5, 2.5, 1, 1, 0.5 and 1, respectively. The Gensini score was calculated by multiplying severity scores with their respective segment multiplying factors. All procedures were approved by the Ethics Committee of Linyi People’s Hospital (Linyi, China). Written informed consents were obtained from all patients or their families.

Samples. Plaque tissues and adjacent artery intimal tissues (serving as the controls) were obtained from all patients by coronary endarterectomy and stored in liquid nitrogen until further use. In addition, peripheral blood was collected from all patients and healthy subjects (control) for the separation of serum by centrifugation at a speed of 400 x g at 4°C for 10 min. In order to obtain PBMCs, a mixture of the heparin anticoagulated venous blood and equal amount of serum-free Iscove’s modified Dulbecco’s medium (v/v, 1:1; P12440053; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was added to the lymphocyte separation medium prior to centrifugation at a speed of 400 x g for 30 min at room temperature. Following centrifugation, the middle layer was aspirated and the supernatant was added to the lymphocyte separation medium prior to centrifugation at a speed of 400 x g for 30 min at room temperature.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Serum (1 ml) was mixed with 1 ml TRIzol reagent (cat. no. 10606ES60; Yeasen Biotechnology Co., Ltd., Shanghai, China) for lysis. Next, total RNA was extracted using miRNeasy Serum/Plasma kit (cat. no. JL217184; Guangzhou Jianlun Biological Technology Co., Ltd., Guangzhou, China). The purity of RNA was then determined by measuring the absorbance at 260/280 nm using ultraviolet spectrophotometry (Nanodrop ND-1000; Thermo Fisher Scientific, Inc.). Subsequently, cDNA was obtained by reverse transcription using TIANScript II cDNA First Strand Synthesis kit (cat. no. KR107; Tiangen Biotech Co., Ltd., Beijing, China) from 1 µg RNA and stored at -20°C.

SuperReal PreMix (SYBR-Green) kit (Tiangen Biotech Co., Ltd.) was used to detect the mRNA expression of COX-2, using β-actin as an internal reference. The reaction system (total volume, 20 µl) was composed of 10 µl qPCR Mix, 0.5 µl upstream primer (COX-2 mRNA, 5'-CAGCCATAC AGCAATCCCTTG-3'; β-actin, 5'-CACCAAGGGCTGTAGT GT-3'), 0.5 µl downstream primer (COX-2 mRNA, 5'-CAA ATGTGATCCTGATGTCACG-3'; β-actin, 5'-CTCACEACT GATCCTGGCAT-3'), 1 µl cDNA and 8 µl ddH2O. qPCR was conducted under the following condition: Initial denaturation at 95°C for 30 sec; 40 cycles of denaturation at 95°C for 5 sec and annealing at 60°C for 34 sec (iQ5 Reverse transcription PCR Detection System; Bio-Rad Laboratories, Inc., Hercules, CA, USA). The 2-ΔΔCq method (16) was used to calculate the relative expression of COX-2 mRNA against β-actin. Each sample was tested in triplicate.

The expression of miR-381 was determined by miReute miRNA qPCR detection kit (cat. no. FP401; Tiangen Biotech Co., Ltd.), using U6 as an internal reference. The reaction system (total volume, 25 µl) contained 12.5 µl SYBR Premix Ex Taq, 1 µl upstream primer (miR-381, 5'-ACACTCCCG AGTGGTACAAAGGGCAAGCT-3'; U6, 5'-CTGCTCTCG GACGACA-3'), 1 µl downstream primer (miR-381, 5'-TG TCGTGAGACGTG-3'; U6, 5'-AAGCTTCAGAATT TGCGT-3'), 2 µl template and 8.5 µl ddH2O. The reaction protocol was as follows: Initial denaturation at 95°C for 5 min; 40 cycles of denaturation at 95°C for 15 sec, annealing at 60°C for 30 sec and elongation at 72°C for 30 sec (iQ5; Bio-Rad Laboratories, Inc.). The 2-ΔΔCq method was used to calculate the relative expression of miR-381 against U6. Each sample was tested in triplicate.

Western blotting. Tissues and cells were collected and mixed with 100 µl precooled radioimmunoprecipitation assay lysis buffer (P0013B; Beyotime Institute of Biotechnology, Shanghai, China) containing 1 mM phenylmethylsulfonyl fluoride for lysis for 15 min at 4°C. Next, the mixture was centrifuged at 12,000 x g at 4°C for 5 min. The supernatant was used to determine the protein concentration with a bicinchoninic acid protein concentration determination kit (cat. no. RTR7102; Real-Times Biotechnology Co., Ltd., Beijing, China). Protein samples were then mixed with sodium dodecyl...
sulfate (SDS) loading buffer prior to denaturation in a boiling water bath for 5 min. Subsequently, the samples (20 µg) were subjected to 10% SDS-polyacrylamide gel electrophoresis. The resolved proteins were transferred to polyvinylidene difluoride membranes on ice (100 V; 2 h) and blocked with 5% skimmed milk at room temperature for 1 h. The membranes were then incubated with rabbit anti-human COX-2 polyclonal primary antibody (1:1,000; cat. no. ab15191; Abcam, Cambridge, UK) and rabbit anti-human β-actin primary antibody (1:5,000; cat. no. ab129348; Abcam) at 4°C overnight. Following washing three times for 5 min each, with phosphate-buffered saline with Tween-20 (TBST), the membranes were incubated with polyclonal goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (1:3,000; cat. no. ab6721; Abcam) for 1 h at room temperature, followed by washing with TBST for three times for 15 min each. Subsequently, the membrane was developed with an enhanced chemiluminescence detection kit (cat. no. ab65623; Abcam) for imaging. Image Lab version 3.0 software (Bio-Rad Laboratories, Inc.) was used to acquire and analyze imaging signals. The relative expression of COX-2 protein was calculated against that of β-actin.

Enzyme-linked immunosorbent assay (ELISA). Blood samples were centrifuged at a speed of 1,000 x g at 4°C for 10 min and serum was tested using a COX-2 ELISA kit (cat. no. KBI567; Shanghai Kemin Biotech Co., Ltd., Shanghai, China). Standards (50 µl; provided by the kit), serum samples (10 µl sample liquid and 40 µl diluent) and blanks were added into the predefined wells of a 96-well microplate. In the standard and serum wells, horseradish peroxidase-labelled conjugates (100 µl) were added prior to sealing the plates for incubation at 37°C for 1 h. Subsequent to five washes using wash liquid (part of the kit), substrates A (50 µl) and B (50 µl) were added into each well. After incubation at 37°C for 15 min, stop solution (50 µl) was added into each well and the absorbance was measured at 450 nm within 15 min.

Dual-luciferase reporter assay. Bioinformatics prediction is a powerful tool used to study the functions of miRNAs. In order to understand the regulatory mechanism of COX-2 in coronary atherosclerosis, the online software miRanda (www.microma.org/mirhome/home.do), TargetScan (www.targetscan.org), PITA (genie.weizmann.ac.il/pubs/mir07/mir07_data.html), RNAhybrid (bibiserv.techfak.uni-bielefeld.de/rnahybrid) and PicTar (pictar.mdc-berlin.de) were used to predict miRNA molecules that may regulate COX-2. The analysis identified that miR-381 was able to potentially regulate COX-2.

The cells were divided into negative control (NC), wild-type (WT) and mutant groups. According to the bioinformatics results, WT and mutant seed regions of miR-381 in the 3'‑untranslated region (UTR) of the COX-2 gene were chemically synthesized in vitro, added with SpeI and HindIII restriction sites for the insertion of plasmids and then cloned into pMIR-REPORT luciferase reporter plasmids (Ambion; Thermo Fisher Scientific, Inc.). Plasmids (0.8 µg) with WT or mutant 3'-UTR DNA sequences were co-transfected with agomiR-381 (100 nM; Sangon Biotech Co., Ltd., Shanghai, China) into 293T cells [ATCC, Manassas, VA, USA; cultured in 24-well plates containing Dulbecco’s modified Eagle’s medium (Thermo Fisher Scientific, Inc.) and 10% fetal bovine serum (Sangon Biotech Co. Ltd.) at 37°C and 5% CO₂]. Following cultivation for 24 h, the cells were lysed using a dual-luciferase reporter assay kit (Promega Corporation, Madison, WI, USA) according to the manufacturer’s protocol and fluorescence intensity was measured using a GloMax 20/20 luminometer (Promega Corporation). Using Renilla fluorescence activity as an internal reference, the fluorescence values of each group of cells were measured.

Statistical analysis. The results were analyzed using SPSS version 18.0 statistical software (SPSS, Inc., Chicago, IL, USA). The data are expressed as the mean ± standard deviation. Data were tested for normality and multigroup measurement data were analyzed using one-way analysis of variance. In case of homogeneity of variance, the least significant difference and Student-Newman-Keuls methods were used, whereas in case of heterogeneity of variance, Tamhane’s T2 or Dunnett’s T3 method was used. P<0.05 indicated statistically significant differences.

Results

COX-2 mRNA expression is upregulated in the plaque tissues, PBMCs and serum of patients with coronary atherosclerosis. To measure the expression of COX-2 mRNA, RT-qPCR was employed. The data demonstrated that the levels of COX-2 mRNA in the plaques, PBMCs and serum of patients with coronary atherosclerosis were significantly higher when compared with those in normal adjacent tissues or healthy subjects (P<0.05; Fig. 1). These results suggested that upregulation of COX-2 mRNA in plaque tissues, PBMCs and serum was associated with the occurrence of coronary atherosclerosis.

Increased expression of COX-2 protein in plaque tissues and PBMCs suggests its regulatory role in coronary atherosclerosis. To determine COX-2 protein expression in plaque tissues and PBMCs, western blotting was used. The data revealed that COX-2 protein levels in plaque tissues and PBMCs from patients with coronary atherosclerosis were significantly elevated compared with those in the corresponding control groups (P<0.05; Fig. 2). The results indicated that increased expression of COX-2 protein in the plaque tissues and PBMCs may serve a regulatory role in coronary atherosclerosis.

Secretion of COX-2 protein into the blood by PBMCs is promoted in coronary atherosclerosis. To examine the contents of COX-2 protein in the serum, ELISA was conducted. The data indicated that the serum level of COX-2 protein in patients with coronary atherosclerosis was significantly higher in comparison with that in healthy subjects (P<0.05; Fig. 3). These findings suggested that the secretion of COX-2 protein into the blood by PBMCs was promoted in coronary atherosclerosis.

miR-381 may serve a regulatory role in the pathogenesis of coronary atherosclerosis. To study the expression of miR-381, RT-qPCR was performed. The results revealed that the levels of miR-381 in plaque tissues, PBMCs and serum obtained from patients with coronary atherosclerosis were significantly reduced as compared with the corresponding
miR-381 regulates the expression of COX-2 by directly binding with the 3'-UTR of COX-2. Analyses performed using miRanda, TargetScan, PITA, RNAhybrid and PicTar demonstrated that miR-381 may target COX-2 (data not shown). To test whether miR-381 directly targets COX-2, dual-luciferase reporter assay was performed. The data demonstrated that transfection with agomiR-381 and pMIR-REPORT in the WT group resulted in a significantly reduced fluorescence intensity compared with the negative control (P<0.05). By contrast, fluorescence intensity in the mutant group was not significantly different from that in the negative control (P>0.05; Fig. 5). These observations suggest that miR-381 regulated the expression of COX-2 by directly binding with the 3'-UTR of COX-2.

Discussion

During the occurrence and development of chronic inflammation, COX-2 serves an important role. COX-2 is induced by external stimuli (physical, chemical or biological factors) and participates in inflammatory reactions by catalyzing the synthesis of prostaglandins (17). Due to the importance of COX-2 in inflammation, high expression of COX-2 in tissues has become a significant marker of inflammation (18). In addition to antipyretic and analgesic effects, COX-2 inhibitors
Figure 3. Expression of COX-2 protein in the (A) plaque tissues and (B) PBMCs obtained from patients with coronary atherosclerosis. Western blotting was employed to measure the protein expression. *P<0.05 and **P<0.01 vs. control group. COX-2, cyclooxygenase-2; PBMCs, peripheral blood mononuclear cells.

Figure 4. Expression of miR-381 in the (A) plaque tissues, (B) PBMCs and (C) serum of healthy subjects and patients with coronary atherosclerosis. Reverse transcription-quantitative polymerase chain reaction was used to determine the expression of miR-381. *P<0.05 and **P<0.01 vs. control group. COX-2, cyclooxygenase-2; PBMCs, peripheral blood mononuclear cells; miR, microRNA.
can also serve an auxiliary role in antitumor therapy (19). In previous studies, the association between COX-2 and atherosclerosis has been examined. It has been reported that the genetic variation of COX-2 is associated with cardiovascular diseases (20). Another study observed that endotoxin-treated porcine coronary artery contraction induced by bradykinin was achieved via the COX-2 pathway (21). Furthermore, COX-2 is considered to exert certain therapeutic effects in the process of atherosclerosis by selectively inhibiting celecoxib (22). Consistently, the results of the present study revealed that the expression of COX-2 was elevated in the plaque tissues, PBMCs and serum of coronary atherosclerosis patients, suggesting that the onset of this disease is similar to that of vascular intimal inflammation, in which PBMCs and lymphocytes are activated. These cells secrete a great amount of COX-2 to initiate abundant antigen immune responses.

Previous studies have suggested that miRNA molecules are important in the occurrence and development of various diseases (23,24) and may slice the mRNA of COX-2 and inhibit its translation (25). It has been reported that miR-381 is down-regulated in colon cancer tissues, leading to upregulated liver receptor homolog-1, as well as the proliferation and invasion of colon cancer cells (26). In addition, miR-381, which exists in the negative feedback loop of p53/pituitary tumor-transforming 1, inhibits the growth of hypophysoma (27). miR-381 is also closely associated with multidrug resistance protein 1 gene and serves important roles in multidrug resistance (28). Along with miR-424, miR-381 can target WEE1 gene and inhibit the activity of cyclin-dependent kinase 2 in renal carcinoma cells (29). Furthermore, miR-381 is also closely associated with lung adenocarcinoma (30). These previous studies suggested that miR-381 expression may be closely correlated with various human diseases.

According to bioinformatics prediction conducted in the present study, miR-381 was predicted to be a potential upstream regulator of COX-2. The data of the present study suggested that miR-381 expression was downregulated and COX-2 was upregulated in the plaques and PBMCs of coronary atherosclerosis patients. This suggests that the body may decrease miR-381 levels to negatively regulate its slicing effect on COX-2, while enhanced expression of COX-2 then produces immune responses. Similar results were observed in the serum of patients, indicating that increased COX-2 in PBMCs can also be released into the blood. Therefore, the levels of miR-381 and COX-2 in the serum may reflect the degrees of inflammation responses and tissue injuries in coronary atherosclerosis. Notably, the current study data of dual-luciferase reporter assay revealed that miR-381 directly binds with the 3'-UTR of COX-2 mRNA and regulates the expression of COX-2.

In conclusion, the present study demonstrated that enhanced levels of COX-2 expression in patients with coronary atherosclerosis were associated with the downregulation of miR-381 expression. Thus, miR-381 may regulate the occurrence and immune responses of coronary atherosclerosis via COX-2.

Acknowledgements

The authors would like to thank the doctors and nurses at the Linyi People's Hospital (Linyi, China) who assisted in the plasma specimen and clinical data collection.

Funding

No funding was received.

Availability of data and materials

The analyzed data sets generated during the present study are available from the corresponding author on reasonable request.

Authors' contributions

KS and LL conceived and designed the study. LL and GS performed the experiments and collected the data. KS and YW wrote the paper and interpreted the data. KS and LL reviewed and edited the manuscript. All authors read and approved the manuscript.

Ethics approval and consent to participate

All procedures were approved by the Ethics Committee of Linyi People's Hospital (Linyi, China). Written informed consents were obtained from all patients or their families.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


